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Abstract
Background: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the
L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir,
Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistance, L76V is also discussed to
confer hypersusceptibility to the drugs Atazanavir and Saquinavir which might enable new treatment strategies by
trying to take advantage of particular mutations.
Results: Based on a cohort of 47 L76V-positive patients, we examined if there might exist a clinical advantage for L76V-
positive patients concerning long-term success of PI-containing regimens in patients with limited therapy options.
Genotypic- and phenotypic HIV-resistance tests from 47 mostly multi-resistant, L76V-positive patients throughout
Germany were accomplished retrospectively 1999-2009. Five genotype-based drug-susceptibility predictions
received from online interpretation-tools for Atazanavir, Saquinavir, Amprenavir and Lopinavir, were compared to
phenotype-based predictions that were determined by using a recombinant virus assay along with a Virtual
Phenotype™(Virco). The clinical outcome of the L76V-adapted follow-up therapy was determined by monitoring
viral load for 96 weeks.
Conclusions: In this analysis, the mostly used interpretation systems overestimated the L76V-mutation concerning
Atazanavir- and SQV resistance. In fact, a clear benefit in drug susceptibility for these drugs was observed in
phenotype analysis after establishment of L76V. More importantly, long-term therapy success was significantly
higher in patients receiving Atazanavir and/or Saquinavir plus one L76V-selecting drug compared to patients
without L76V-selecting agents (p = 0.002).
In case of L76V-occurrence ATV and/or SQV may represent encouraging options for patients in deep salvage
situations.
Background
The reduced susceptibility to certain antiretrovirals is
often accompanied with a gradual loss of viral fitness,
indicating that mutations with high fitness costs are less
able to persist in the absence of drug pressure [1].
There have been recent reports about HIV strains with
increased susceptibility to particular drugs when certain
mutation patterns had developed under antiretroviral
treatment [2-5]. This biological attribute enables new
putative strategies for future treatment of HIV-infected
patients with abundant resistance mutations by trying to
take advantage of particular mutations [6].
As example, M184V/I, the most prevalent NRTI-
mutations selected under 3TC or FTC in the reverse
transcriptase, do for instance revert partially the effect
of thymidine-analogue mutation- (TAM) on resistance
[7]. K65R and L74V are further mutations which can
confer hypersusceptibility or resensitization to AZT [8].
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tase, there are also reports about resensitizing mutations
affecting the protease gene [9,10].
Objectives
This article reports about possible clinical advantages of
a valine substitution, instead of leucine, at position 76 in
the HIV-1 protease. This mutation generally disappears
quickly in replicating viruses in absence of selection
pressure mediated by LPV, APV or DRV treatment.
Thus, for deep salvage therapy situations in patients
with strongly limited therapy options, it might be of
advantage to maintain these drugs in treatment regi-
mens to preserve L76V in the current replicating virus
in combination with a “resensitized” drug ATV or SQV.
Results
Patients with protease gene mutation L76V show
increased susceptibility for Atazanavir and Saquinavir
At first, the impact of L76V on ATV- and SQV-
resistance characteristics was assessed before and after
establishment of the mutation. Due to the manifestation
of the L76V mutation as well as other minor mutations
at resistance-relevant sites in the course of treatment,
genotype-based interpretation tools predicted intermedi-
ate or mostly complete resistance against all PIs includ-
ing ATV and SQV and the majority of NRTIs and
NNRTIs resulting in an active drug score (ADS) of ≤
1.0 for the failing regimen (Figure 1). Interestingly, in
phenotypic analysis, the resistance factor (RF) for ATV
and SQV remained at full susceptibility in both
patients and even decreased for SQV from 31 to 1.1
(Figure 1A) and 1.1 to 0.6 (Figure 1B) and for ATV
from 62 to 2.8 and 4.3 to 0.9, respectively.
In a further aspect, genotypic and phenotypic resis-
tance data of 10 patients, all L76V positive, was assessed
in order to analyze if these observed resensitizing effects
represent ubiquitous drug resistance patterns. Figure 2
supports this hypothesis on a variety of other patients
harbouring HIV populations with L76V mutation. The
accuracy and concordance of predicted genotype-based
interpretations were compared with obtained phenotypic
No L76V Detected L76V A B No L76V Detected L76V
APV, d4T, EFV Therapy
APV,
d4T,
EFV
Viral load 143,830 copies/mL 10,700 copies/mL
TDF, IDV, LPV Therapy
Viral load 11,488 copies/mL 859,000 copies/mL
d4T,
ddI,
SQV
Phenotype Phenotype
L10I, L24I, M46L, I54V,
A71V G73S V82A
L10I, K20R, L33F, M46L, 
I54I/L A71V L76V G73S
Protease
Genotype
Protease
Genotype
Max. Resistance Resistance Factor (present sample) Max. Resistance Resistance Factor (present sample)
L10I, M46I, I54V, V82F  L10I, K20R, M46I, I54V, 
A71V L76V V82F A71V, G73S, V82A I54I/L, A71V, L76V,G73S,
V82A, I84V
Genotype
Resistance
Prediction
REGA
ANRS
REGA
ANRS
Genotype
Resistance
Prediction
REGA
ANRS
REGA
ANRS
A71V,L76V,V82F
ANRS
HIVdb 3.6
HIVGrade
Phenotype
ANRS
HIVdb 3.6
HIVGrade
Phenotype
ANRS
HIVdb 3.6
HIVGrade
Phenotype
ANRS
HIVdb 3.6
HIVGrade
Phenotype
Resistant Intermediate Sensitive Resistant Intermediate Sensitive
Figure 1 Resensitizing effects of the L76V mutation are visible in phenotype results: Phenotypic resistance analysis before and after
manifestation of L76V in two representative patients (A+B). Although additional mutations developed in the progress of therapy (bold
characters) the resistance factor for ATV and SQV decreased below the cut-off for full susceptibility in both patients compared to analyses one
year before. Antiretroviral drugs are illustrated with corresponding resistance factors (cut-off: 0-3.5 = sensitive 3.6-9.5 (29 for LPV) = intermediate;
>9.0 (29 for LPV) = resistant). Genotypic resistance interpretations derived from five common online tools showed considerable discrepancies in
weighting of ATV and SQV resistance levels compared to each other and to phenotypic results (grey and white colour). A) One patient with
failing APV containing therapy after week 72. B) Another patient with a failing IDV/LPV treatment before start of SQV containing therapy.
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tual phenotype analysis.
Despite a general concordance in genotype- and phe-
notype-based resistance predictions for LPV and APV,
there were wide discrepancies in the weighting of resis-
tance for ATV and SQV, mostly overestimation of resis-
tance in genotype-based predictions (Figure 2).
However, most phenotypic resistance interpretations
uncovered full susceptibility for the drugs ATV and
SQV. In most cases L76V appeared to be associated
with a variety of other resistance relevant protease
mutations without effecting the resensitizing effect.
However, in particular, the copresence of the protease
mutation L90 M was notably associated with high ATV
and SQV resistance factors (Figure 2; #4, #26, #21).
Clinical outcome and follow-up in patients with L76V-
adapted therapy
Considering the effect of L76V on susceptibility for
ATV and SQV, the big question was obviously, how this
mutation might affect the therapeutic option and strat-
egy for patients with a narrow margin of remaining
active drugs. A considerable issue remained to general-
ize data from a small cohort of patients with diverse
optimized backbone therapies. Thus, this work focused
on the amount of active drugs in the treatment of each
patient. Table 1 shows the L76V-adjusted follow-up
therapies that were administered after resistance predic-
tion results.
Sufficient virus suppression below the detection limit
was initially observed in 50% of group A (ATV and/or
L10V, M46I, I54V, 
L63P, L76V, V82A
L10I, L24I, L33F, M46I, 
I54V, L63P, A71V, L76V, 
V82A
L10I, L24I, L33F, M46L, 
I54L A71V, G73S, L76V, 
V82A,I84V
#28
NRTI
LPV
PI ATV PI NRTI
LPV
ATV 
#29
ATV PI NRTI
LPV
#17
L10F, K20K/R, M46I, 
I54V L63P, L76V, V82F
ATV PI NRTI
LPV
#9
ATV PI NRTI
LPV
L10I, K20I, M36I, M46I 
I54L, L76V, I84V
#5
NNRTI
LPV
APV
SQV
LPV
APV
SQV NNRTI
APV
SQV NNRTI NNRTI
APV
SQV NNRTI
APV
SQV
REGA
ANRS
HIVdb 3.6
HIVGrade
geno2pheno
Phenotype
#1 #8 #4 #26 #21
K20R, V32I, M46I, 
L76V, V82A
L10F, K20I, M36I, M46I, 
I50V, I54I/V, L63P, L76V 
L10V, K20K/R, M36I, M46I, 
L63P, L76V, L90M
L10I, K20R, M36I, M46I 
I54V, L76V, V82F, L90M
L10I, F53L, I54V, A71V, 
L76V, V82A, I84V, L90M
geno2pheno
Vircotype
PI
NNRTI
NRTI APV
SQV
ATV PI
NNRTI
NRTI
LPV
APV
SQV
ATV PI
NNRTI
NRTI
LPV
APV
SQV
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NNRTI
NRTI
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NRTI
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HIVGrade
NNRTI
HIVGrade
Resistant Intermediate Sensitive
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Figure 2 The “resensitizing” effect of 76V could be observed in a variety of other patients before start of PI-containing therapy.
Genotypic and phenotypic data of 10 representative PI-experienced patients were analysed by using five common resistance interpretation
systems Stanford HIVdb 4.3.6; REGA v7.1.1, HIV-Grade 04/2008, ANRS 10/2007 and geno2pheno. Genotypic resistance results were compared to
phenotypic resistance results derived from recombinant virus assay results and/or Virtual Phenotype™ analysis (Virco).
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( A T Va n d / o rS Q Vp l u sL 7 6 V -selecting drug LPV or
APV) within the first weeks of follow-up therapy.
Despite similar response rates at first, a sustained ther-
apy success with virus suppression still below 50 copies/
mL at week 96 and longer was predominantly achieved
in group B patients where the selection pressure on
L 7 6 Vw a sc o n s t a n t l ym a i n t a i n e db yt h ed r u g sL P Vo r
APV (Table 1, lower rows). While 66.7% of group B
patients remained under detection levels at week 96,
there was a significantly lower success rate in group
A patients with 16.7% remaining <50 copies/mL in per-
protocol analysis (p = 0.002; c
2 test) (Table 2 and
Figure 3). Patients of group C did not show any virus
suppression below detection limit.
Interestingly, despite a successful virus suppression <50
copies/mL, the majority of group B therapies were
expected to have an ADS below 2.0 after genotypic resis-
tance predictions, indicating a very likely event of therapy
failure (bold numbers in square brackets) (Table 1).
Most of the cases where therapies were predicted to
have active drug scores of ≥2.0 turned out to be suc-
cessful. Only few experienced virological failure despite
an ADS of more than 2.0 (indicated in round brackets).
A major question remained obviously, why patients of
group A display earlier therapy failures than patients of
group B. After two years of follow-up therapy, only one
patient of group A, who additionally received a fusion-
inhibitor containing treatment, showed a viral load still
below 50 copies/mL. The median viral load increased
after 24 weeks of follow-up in group A (Figure 3). More
interestingly, due to a loss of selection pressure on the
L76V mutation, it was then undetectable in those
patients who failed therapy, resulting in a decrease of
the ADS below <2.0 (Table 3). While L76V was unde-
tectable in patients where no L76V-selecting drug was
applied, it persisted in group B and group C where
selection pressure on mutation L76V was maintained
(Table 3). In these patients the therapy failure had other
reasons (e.g. acquisition of L90M).
These results additionally indicate benefits for patients
with L76V-selecting drugs in combination with L76V-
"resensitized” drugs. A major issue remains the estab-
lishment of additional protease gene mutations i.e. L90
M and further compensatory changes over the time
(Figure 2; #4, #21, #26), making it crucial to suppress
the virus completely and monitor viral load in close
intervals.
Discussion
Little is known about the impact of drug-resensitizing
mutations on antiretroviral therapy. Most works mainly
describe the effects of resistance mutations on reduc-
tions in drug susceptibility. However, selective pressure
of drug therapy may also lead to shifts in the quasispe-
cies distribution and fitness of those mutants with
decreased sensitivity to the respective antiretrovirals
[11,12]. This loss in replication fitness may be even lar-
ger for a multi-drug resistant virus and might lead to a
better starting point for particular antiretroviral regi-
mens [13]. Nevertheless, it is not always applicable that
the acquisition of drug-resistance mutations inevitably
result in loss of viral fitness. Even in case a loss is
apparent, the virus may select compensatory changes
over time [12,14]. This may explain why current treat-
ment guidelines still advocate a switch to antiretroviral
treatment regimens following the emergence of drug
resistance mutations and possibly prior to selection of
compensatory changes [11]. In summary, drug hypersus-
ceptibility mutations which reduce viral fitness are diffi-
cult to maintain in the predominant virus population in
multiple pretreated patient.
In this article we provide insights into a possibility
how to maintain efficient selection pressure on the pro-
tease mutation at position L76V by combining one
drug, which selects L76V (in this case LPV, APV, DRV)
and another drug which gains efficiency when L76V
develops. This article reports about a significant clinical
benefit of the protease mutation L76V on drug suscept-
ibility to ATV and SQV due to resensitizing effects in
multi-resistant patients resulting in a significantly higher
long-term therapy success. These results may be in line
with explanations from molecular dynamics- and free
energy studies recently reported by Alcaro et al. who
found that in the presence of the L76V substitution,
ATV reveals a more productive binding affinity, in
agreement with hypersusceptibily data [15].
Conclusion
The strategy of combining mutation-selecting drugs
with “resensitized” drugs has already been discussed for
the reverse transcriptase mutation M184V in NRTI-
containing therapies [6,13,16] and has also been shown
to be an adequate option for a couple of other muta-
tions including the mutation N88 S [10].
Despite initially adequate therapy response rates in
5 0 %( g r o u pA )-6 7 . 7 %( g r o u pB )o fc a s e s ,i tr e m a i n sa
major issue that virological failure under these thera-
pies often occur due to compensatory changes in the
virus genotype over the time mostly due to an addi-
tional establishment of further mutations in the
respective gene [12,14]. As shown in Table 3, failure of
therapy in L76V-positive patients with ATV and/or
SQV containing therapy was noticeable associated with
an additional establishment of the protease gene muta-
tion at position L90 M which resulted in resistance
against all available PIs [17]. Six of eight patients who
received a second genotypic resistance test following
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Page 4 of 9Table 1 Active drug score (ADS) for the follow-up therapy
GROUP A GROUP B
Pat-ID #1 #2 #4 #12 #14 #17 #18 #21 #22 #46 #3 #5 #8 #9 #10 #11 #16 #19 #24 #25 #26 #27 #31 #33 #37 #39 #40 #41
Therapy ATV
SQV
RTV
FTC
ATV
SQV
RTV
3TC
ATV
SQV
RTV
ATV/r
SQV
3TC
T20
SQV
TPV/r
3TC
ddI
ddI
d4T
SQV
ATV
SQV
3TC
T20
ATV
EFV
TDF
AZT
3TC
MVC
ATV/r
SQV
AZT
3TC
TDF
SQV/
r
TDF
FTC
LPV/r
SQV
3TC
d4T
TDF
LPV/r
ATV
AZT
3TC
LPV/r
SQV
d4T
LPV/r
SQV
ENF
LPV
ATV
FTC
TDF
LPV/r
ATV
EFV
LPV/r
SQV
LPV/r
SQV
APV
SQV
TDF
APV
SQV
ddC
d4T
APV/r
SQV
LPV/r
SQV
FTC
TDF
LPV/r
SQV
3TC
ETR
LPV/r
SQV
AZT
3TC
TDF
LPV/r
SQV
ddI
3TC
LPV/r
SQV
TDF
LPV/r
SQV
TDF
MVC
LPV/r
ATV
TDF
AZT
ABC
3TC
Rev.-
Transcriptase
mutations
41L
44D
67N
98G
103N
118I
210F
215Y
219R
41L
67ss
69S
188L
215Y
41L
118I
184V
215Y
41L
44A
67N
75I
103N
108I
118I
210W
215Y
41L
67N
69D
70R
74V
103N
181C
210W
215F
219Q
67N
70R
103NS
190A
184V
219Q
41L
67N
69E
75I
103N
108I
118I
178M
210W
215Y
41L
67N
74V
101Q
184V
215Y
41L
44D
67N
101E
103N
118I
184V
210W
215Y
219E
n.d. 41L
67ss
69S
101Q
181C
190S
215Y
65R
70R
103N
108I
115F
151M
179E
184V
219E
67N
184V
210W
215Y
219Q
41L
44D
67N
75L
118I
181C
184V
190A
210S
215Y
41L
44D
67N
70R
190A
227L
184V
210W
215F
219R
41L
67N
74V
98G
118I
184V
210W
215Y
227L
41L
44D
103N
118I
184V
210W
215Y
no
data
no
data
no
data
67N
70R
103S
184V
190A
215F
219Q
41L
67N
75I
118I
210W
215F
41L
44A
67N
75M
101Q
118I
184V
210W
215F
41L
74V
101Q
103N
108I
181C
190A
210W
215Y
41L
44D
67G
103N
118I
184V
210W
215F
67N
70R
215I
219Q
67N
70R
215I
219Q
41L
67N
70R
184V
Protease
mutations
10F
20I
36I
46I
50V
54I/V
76V
10V
46I
47V
71V
76V
77I
10V
20R
36I
46I
76V
90M
10I
33F
46L
76V
82F
90M
10V
20R
33F
36I
54V
73S
76V
90M
10F
20R
46I
54V
63P
76V
82F
10I
33F
36L
46L
76V
82F
84V
90M
10I
53L
54V
71V
76V
77I
82A
84V
90M
10I
33F
46L
54V
71I
76V
77L
82A
90M
10I
33V
60E
76V
10V
46L
54V
63P
71V
82A
93L
10I
20I
36I
46I
54L
76V
84V
20R
32I
46I
76V
82A
10I
24I
33F
46I
54V
63P
71V
76V
82A
10V
20I
36I
46I
47V
53L
76V
84V
90M
10F
33F
46L
54L
71V
76V
77I
84V
90M
10F
46I
54M
71V
76V
82A
10I
20R
24I
36I
46I
54V
76V
82C
10F
33F
54V
71V
76V
77I
82A
10I
20R
35D
46I
54V
76V
10I
20R
36I
46I
54V
71V
76V
82F
90M
10I
46I
47V
71V
76V
90M
10I
13V
32I
33F
36I
46I
76V
84V
90M
10F
46I
47V
76V
84V
10R
32I
33F
46I
47V
76V
84V
88S
90M
10F
20I
36I
46I
76V
84V
10V
13V
24I
33F
46I
54V
76V
82A
20I
36I
54V
76V
82A
Active Drug
Scores
HIVdb 4.3.6 [1.5] (2.25) 0.5 [1.75] 0.75 1,25 [1.5] [1.75] 0.25 3.0 1,5 [0.5] [0.75] 1.25 0.25 [0.75] [0.5] [0.5] 1.5 n.d. 0.5 [1.25] [0.25] [1.5] 0.0 [1.0] [1.75] [1.75]
Rega V7.1.1 2.0 (2.75) 1.5 2.0 1.0 1.0 2.0 3.5 0.0 3.0 1.75 [1.0] [1.5] 1.0 0.0 [0.25] [0.75] [0.75] 1.75 n.d. 0.75 [1.0] [0.5] 2.75 0.5 2.0 2.25 4.25
HIVGrade04/
08
2.5 (3.0) 1.5 2.25 1.0 0.5 2.75 2.75 0.0 3.0 (2.0) [1.0] [1.0] (2.0) 0.0 [1.0] [1.0] [1.0] (2.0) n.d. 1.0 [1.75] [0.0] [1.75] 0.0 [0.75] 2.0 2.0
ANRS 10/
2007
3.0 (2.0) 0.5 [1.0] 1.0 1.0 2.0 2.5 0.5 3.0 1.5 [0.0] 2.0 1.0 0.5 [1.0] [1.0] [0.5] (2.0) n.d. 0.5 2.0 [0.5] 2.5 1.5 [1.5] 2.5 3.0
geno2pheno 2.0 (3.0) 1.0 2.5 (2.0) n.d. n.d. 2.0 n.d. 3.0 (2.0) [0.5] [0.5] 1.5 0.0 [1.0] n.d. n.d. n.d. n.d. 0.0 2.5 n.d. 2.0 0.0 1.0 2.0 4.0
VircoType 2.25 (2.0) (2.0) 2.5 1.5 n.d. n.d. 3.5 n.d. 3.0 2.5 2.0 2.0 1.0 0.5 [0.5] [1.0] [1.0] n.d. n.d. 0.5 [1.0] [1.0] 3.0 1.5 2.0 3.0 3.5
Phenotype 2.5 n.d. 0.0 n.d. n.d. (3.0) 3.0 3.0* n.d. n.d. n.d. 2.5 2.5 (2.0) n.d. n.d. n.d. [0.5] n.d. n.d. 0.0 n.d. n.d. n.d. n.d. n.d. n.d. n.d.
Follow-up
Baseline VL 1070 160000 26900 3231 47653 859000 7700 27000 35400 4248 6680 25900 4840 31400 39000 20163 8751 8800 88100 16100 310510 < 50 72100 14900 1300 744 2078 443
Lowest VL
(12-96
weeks)
< 50 3410 38700 < 50 4943 190 < 50 < 50 1020 < 50 1320 < 50 < 50 116 24000 < 50 < 50 < 50 559 < 50 18270 < 50 < 50 < 50 1300 < 50 < 50 < 50
VL at week
96
13589 46570 152000 < 50 20626 LFU LFU LFU 16500 LFU LFU < 50 < 50 116 LFU < 50 < 50 LFU LFU 1777 LFU 391 60 < 50 LFU < 50 < 50 < 50
Based on five genotypic resistance interpretation tools as well as two phenotypic resistance tests, an active drug score (ADS) for the follow-up therapy was calculated by adding the activity score for every active drug
ranging from AS = 1.0 for complete sensitivity, AS = 0.75 for potential low-level resistance, AS = 0.5 for intermediate resistance, AS = 0.25 for possible resistance and AS = 0.0 for complete resistance. Their prediction on
follow-up therapy was then compared with the virological response in a time frame of 96 weeks. Sucessfull therapies despite an active drug score prediction of <2 are displayed in bold and square brackets. Unsucessfull
therapies despite an active drug score prediction of ≥2 are displayed in round brackets. LFU=loss of follow-up.
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9therapy failure were diagnosed positive for L90 M. The
remaining two were therapy non-compliant. Thus, it
might be questionable if SQV, which primarily selects
L90 M should be replaced in favour of ATV [18-20].
In addition, due to the approval of new drug classes
over the past years one might err on the side of cau-
tion to supplement therapy regimens with new drugs.
Due to the low potency of the present cohort and
varying amounts of HIV non-B infected individuals in
the examined patient groups, caution should be addi-
tionally advised, since these limitations might have
effect on clinical outcomes.
Nevertheless, since there are still distinct discrepan-
cies, mostly overestimation of resistance, in the predic-
tion of the resistance level for Atazanavir and
Saquinavir in five of the most common genotypic inter-
pretation systems, there is still a need for further evalua-
tion in the case of L76V occurrence.
Table 2 Comparison of results (group A and group B)
Virus Suppression Therapy success
Group A
Median
Viral load
Group B
Median Viral load
Mann-Whitney Group A
Success
Group B Success c2
Baseline 26,950
(N = 10)
8,800
(N = 17)
P = 0.12 0%
(N = 10)
5.9%
(N = 17)
P = 0.998
Week 12 370
(N = 10)
<5 0
(N = 15)
P = 0.07 40.0%
(N = 10)
66.7%
(N = 15)
P = 0.035
Week 24 4650
(N = 8)
<5 0
(N = 13)
P = 0.16 37.5%
(N = 8)
69.2%
(N = 13)
P = 0.166
Week 48 3410
(N = 7)
<5 0
(N = 13)
P = 0.19 42.9%
(N = 7)
53.8%
(N = 13)
P = 0.425
Week 96 15,045
(N = 6)
<5 0
(N = 9)
P = 0.044 16.7%
(N = 6)
54.5%
(N = 9)
P = 0.002
Comparison of results (group A and group B). Median viral loads and the therapy success rates illustrate a significantly better long-term suppression of HIV when
SQV/ATV plus optimized backbone therapy is combined with a L76V-selecting drug. In bivariate analysis, these results were independent from slightly different
baseline viral loads ( < 0,5log) between group A and B.
Figure 3 Clinical outcome and suppression of viral load in a time frame of 96 weeks of follow-up therapy (illustrated as box plot
figure). Median viral loads are illustrated in bold lines in between the upper- and lower quartile. Group B (ATV and/or SQV plus LPV or APV
containing treatment) show a higher long-term success rate after 96 weeks of follow-up therapy in comparison to group A (ATV and or SQV
without L76V-selecting drug).
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Clinical material
HIV strains of 46 intensely pretreated (34 showed
NRTI/NNRTI/PI resistance/12 showed NRTI/PI resis-
tance) and one naïve with transmitted mutation, L76V-
positive patients derived from 24 centres throughout
Germany between 1999-2009 were retrospectively ana-
lysed for HIV-resistance patterns and success of fol-
low-up therapy. The inclusion criterion is provided in
Figure 4. Descriptional statistics concerning person-to-
person variations of virological and immunological
parameters were assessed at baseline before switch of
therapy and are provided in Table 4.
All patient data was categorized in three groups con-
cerning the follow-up therapy:
Group A: ATV and/or SQV (no selection pressure on
L76V)
Group B: LPV or APV plus ATV or SQV (maintained
selection pressure on L76V)
Group C: LPV or APV plus other drugs (maintained
selection pressure on L76V)
All patients received an optimized backbone therapy.
HIV-1 RNA Quantification
Plasma of patients was analysed at baseline and week 12,
24, 48 until end of investigation at week 96 to monitor
efficiency of therapy. Plasma RNA was measured by
using the COBAS AMPLICORH I V - 1M o n i t o rs y s t e m
and the Abbott m2000sp/rt system according to the
manufacturer’s recommendations.
Genotypic resistance testing
Plasma samples of all 47 patients were collected and
stored at -20°C until time of RNA extraction. All speci-
mens were processed by using the FDA-approved Sie-
mens HIV TruGene system as well as the Abbott HIV-1
Genotyping System on the Applied Biosystems’ 3100
capillary electrophoresis platform according to the man-
ufacturer’s recommendations. HIV-1 genotypes were
processed and analyzed by using the wildtype LAV-1
sequence as reference. The sensitivity for detecting
minor quasispecies variants was 15%. In this cohort,
only patients with major L76V positive population were
included. Minor wildtype variants were not detected at
this position.
Phenotypic resistance testing
Phenotypic resistance analysis of the complete protease
gene and the first 900bp of the RT were performed
according to an earlier described recombinant virus
assay by determining a virus specific resistance factor
[21]. In addition, the Virtual Phenotype™(based on
53,000 paired genotypes and phenotypes) from Virco
was assessed for those patient samples where no recom-
binant virus assay was realizable.
Interpretation of drug resistance
Several algorithms are available worldwide, both in pub-
lic and private domains. The concordance of resistance
predictions was analysed between the five most com-
monly used algorithms [REGA v7.1.1 [22] HIVGrade
Table 3 Compensatory changes in virus genotypes within 96 weeks of follow-up therapy
Group Patient
ID
Protease mutations at start of therapy Time of
therapy
failure
Time of 2nd
genotype
Protease mutations after therapy failure
A #1 L10FL, K20I, M36I, M46I, I50V, I54IV, L63P,
L76V
Week 48 Week 144 L10F, V11I, I13V, K20R, V32I, L33F, M36I, M46I, I47V,
I54M, L63P, A71V, G73S, I84V, L90M
#2 L10V, M46I, I47V, L63P, A71V, L76V, V77I Week 12 Week 48 L63P, V77I
(therapy interruption)
#4 L10V, K20RK, M36I, M46I, L63P, L76V, L90M Week 12 Week 24 L10V, K20R, M36I, M46I, F53L, L63P, I84IV, L90M
#22 L10I, L33F, M46L, I54V, L63P, A71I, L76V,
V77I, V82A, L90M
Week 12 Week 48 L10I, L33F, M46L, F53L, I54V, L63P, A71T, G73S, V77I,
V82A, L90M
B #8 K20R, V32I, M46I, L76V, V82A Week 48 Week 48 K20R, V32I, M36I, M46I, F53FL, L76V, V82A, L90LM
#9 L10I, L24I, L33F, M46I, I54V, L63P, A71V,
L76V, V82A
Week 12 Week 24 L10I, L24I, L33F, M46I, F53L, I54V, L63P, A71V, L76V,
V82A, I84V
#10 L10IV, K20I, M36I, M46I, I47V, F53L, L63P,
A71V, G73 D, L76V, I84V, L90M
Week 12
compliance
Week 48 L10V, K20I, L33I, M36I, M46I, I47V, F53L, L63P, A71V,
G73 D, L76V, I84V, L90M
#27 L10I, M46I, I47V, L63P, A71V, L76V, L90M Week 48 Week 48 L10I, M46I, I47V, L63P, A71V, L76V, I84V, L90M
C #6 L10V, L33F, M46L, I54V, A71V, L63P, A71V,
L76V, V82A
Week 12 Week 96 L10V, K20R, L33F, M36I, M46L, I54V, A71V, L76V,
V82A
#23 L10FIRV, L33F, I54MV, D60E, L63P, A71V,
L76V, V82F
Week 12 Week 24 L10FIRV, L33F, I54MV, D60E, L63P, A71T/V, L76V,
V82F
Compensatory changes in virus genotypes within 96 weeks of follow-up therapy. Patients with failing therapies within the 96 weeks received a second resistance
testing. While L76V was still present in patients receiving L76V-selecting drugs, it was then absent in patients without these drugs (new detected mutation are
underlined). Therapy failure in group B was noticeable associated with an additional establishment of the protease mutation L90 M.
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Page 7 of 9ver.12/2008 [23] ANRS ver.10/2007 [24] Stanford HIVdb
ver.4.3.6 [25] and the geno2pheno online tool [26]] for
the drugs ATV, SQV, LPV and/or APV. Multiple resis-
tance tests in treatment history were cumulatively docu-
mented. In addition, an active drug score (ADS) was
determined in order to analyze the amount of remaining
active drugs in follow-up therapies of each patient (sus-
ceptible = +1/low intermediate = +0.75/intermediate =
+0.5/high intermediate = +0.25/resistant = +0.0). This
ADS allowed a statement concerning the prediction of
Table 4 Patient characteristics and parameters
Parameter Total Group A (N = 10) Group B (N = 18) Group C (N = 19)
Gender
Male 84% 100% 100% 68,7%
Female 16% 0% 0% 31,3%
HIV-1 subtype
Patients with subtype B 69% 80% 64% 67%
Patients with non-B subtype 31% 20% 36% 33%
Treatment history
Mean duration under ART in months (mean) 66 80 88 54
Current active drug score (mean) - 1.5 1.3 0.5
HIV-1 RNA [copies/ml; median]
Baseline 20,163 26,950 8,800 42,600
CD4 cell counts [cells/μl; median]
Baseline 260 291 307 246
Patient characteristics and parameters. All patients were categorized in three groups as described throughout the article: Group A (ATV and or SQV), group B
(ATV and or SQV plus L76V selecting drug LPV, APV or DRV) and group C (L76V selecting drug plus optimized backbone therapy).
Retrospective evaluation of L76V-
positive pts. with virological failure
and complete genotypic data p gy p
(N=47)
Follow-up therapy:
ATV or SQV +
LPV or APV + OBT
(N=18)
Follow-up therapy:
ATV or SQV
+ OBT
(N=10)
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LPV or APV + OBT
(N=19)
k
 
f
o
l
l
o
w
-
u
p
Loss of 
follow-up
(N=4)
Loss of 
follow-up
(N=6)
Loss of 
follow-up
(N=14)
9
6
 
w
e
e
k
Patients week 
96 with VL>50 
cop/mL (N=5)
Patients week 
96 with VL<50 
cop/mL (N=1)
Patients week 
96 with VL>50 
cop/mL (N=4)
Patients week 
96 with VL<50 
cop/mL (N=8)
Patients week 
96 with VL>50 
cop/mL (N=5)
Patients week 
96 with VL<50 
cop/mL (N=0)
2nd resistance 
test (N=4)
2nd resistance 
test (N=4)
2nd resistance 
test (N=2)
Group A Group B Group C
Figure 4 Inclusion criterion for the retrospective analysis of 47 L76V-positive patients.
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cessful therapy should contain at least two active drugs,
preferably three (ADS ≥2.0) [27,28].
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